Skip to main content

Question for Department of Health and Social Care

UIN 67283, tabled on 1 November 2021

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the reasons for NICE's refusal to make Avelumb available on the NHS in England.

Answered on

4 November 2021

We have made no such assessment. The National Institute for Health and Care Excellence (NICE) is an independent body responsible for developing recommendations in line with its published methods and processes.

NICE has published guidance recommending avelumab for use in a number of cancers and it is now available to patients.

NICE is currently developing guidance on the use of avelumab for use in the treatment of urothelial cancer.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.